The development of super immunodeficient models has greatly advanced xenograft studies, but they are not suited to all study types. To select the model best suited for your specific PDX or cell line study, including immuno-oncology applications, researchers must be fully informed and understand the intricacies of working with highly immunocompromised mouse models.